102 patients enrolled across 14 European centers to assess safety and clinical performance of 35 mm and 40 mm Freesolve™ Resorbable Magnesium Scaffolds in long coronary lesions

Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the successful completion of patient enrollment in the BIOMAG™-LL Clinical Study, evaluating the safety and clinical performance of the Freesolve™ Resorbable Magnesium Scaffold (RMS) in 35 mm and 40 mm lengths for the treatment of de novo coronary lesions up to 38 mm. The study reflects Teleflex's commitment to expanding clinical evidence supporting the use of the Freesolve™ RMS in percutaneous coronary intervention (PCI).

BIOMAG™-LL Clinical Study is a premarket, prospective, international, multi-center, single arm trial. The primary endpoint of the study is Target Lesion Failure* (TLF) rate at 12 months, a composite clinical endpoint commonly used to assess the safety and effectiveness of coronary interventional devices. Clinical follow-up is conducted at 1, 6, 12, 36, and 60 months post-procedure.